{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:55:19Z","timestamp":1790117719136,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.prro.2024.10.014","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T10:15:29Z","timestamp":1731147329000},"page":"14-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2441-9338","authenticated-orcid":false,"given":"Abigail","family":"Pepin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Kiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Nicholas","family":"Lukens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipose","family":"Mulugeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil K.","family":"Taunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2024.10.014_bib0001","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2024.10.014_bib0002","series-title":"Presented at: ESMO Congress, September 13, 2024","article-title":"Efficacy of 177Lu-PNT2002 in PMSA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)","author":"Sartor","year":"2024"},{"key":"10.1016\/j.prro.2024.10.014_bib0003","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2024.10.014_bib0004","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00259-014-2713-y","article-title":"Radiation dosimetry and first therapy results with a (124)I\/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy","volume":"41","author":"Zechmann","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.prro.2024.10.014_bib0005","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2024.10.014_bib0006","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: Safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2024.10.014_bib0007","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2024.10.014_bib0008","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): A multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2024.10.014_bib0009","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancetl"},{"key":"10.1016\/j.prro.2024.10.014_bib0010","first-page":"284","article-title":"Comparison of prostate-specific membrane antigen expression levels in human salivary glands to non-human primates and rodents","volume":"35","author":"Roy","year":"2020","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.prro.2024.10.014_bib0011","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.23.00573","article-title":"Prostate-specific membrane antigen\u2013targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: A phase I dose-escalation study of 225Ac-J591","volume":"42","author":"Tagawa","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2024.10.014_bib0012","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2967\/jnumed.118.222307","article-title":"First clinicopathologic evidence of a non\u2013PSMA-related uptake mechanism for 68Ga-PSMA-11 in salivary glands","volume":"60","author":"Rupp","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2024.10.014_bib0013","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00259-022-05982-8","article-title":"Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics","volume":"50","author":"Lucaroni","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.prro.2024.10.014_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102748","article-title":"Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going","volume":"127","author":"Muniz","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.prro.2024.10.014_bib0015","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.ijrobp.2004.12.076","article-title":"Dose\u2013volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy","volume":"62","author":"Blanco","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6_suppl","key":"10.1016\/j.prro.2024.10.014_bib0016","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.2022.40.6_suppl.097","article-title":"Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study","volume":"40","author":"Herrmann","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2024.10.014_bib0017","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1200\/JCO.23.01241","article-title":"How can radiopharmaceutical therapies reach their full potential? improving dose reporting and phase I clinical trial design","volume":"42","author":"Kiess","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2024.10.014_bib0018","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2967\/jnumed.122.264946","article-title":"Developing a patient-reported outcome measure for radionuclide therapy for prostate cancer","volume":"64","author":"Gudenkauf","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2024.10.014_bib0019","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s13139-017-0508-3","article-title":"Injection of Botulinum toxin for preventing salivary gland toxicity after PSMA radioligand therapy: An empirical proof of a promising concept","volume":"52","author":"Baum","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.prro.2024.10.014_bib0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.120.246983","article-title":"The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: A prospective, randomized, double-blind, placebo-controlled intraindividual imaging study","volume":"62","author":"Harsini","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2024.10.014_bib0021","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/MNM.0000000000001506","article-title":"Reduction of radiation accumulation in salivary glands through oral vitamin C during 68Ga-PSMA-11 total-body dynamic PET\/CT imaging","volume":"43","author":"Yu","year":"2022","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.prro.2024.10.014_bib0022","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijrobp.2015.01.050","article-title":"Acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating radiation-induced xerostomia: Results of RTOG 0537 phase 3 study","volume":"92","author":"Wong","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850024002996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850024002996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T04:22:14Z","timestamp":1736310134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850024002996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1879850024002996"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2024.10.014","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2024.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}